Desmopressin 120 mcg, 180 mcg, 240 mcg: The right treatment for the right patient

Pietro Ferrara, Francesca Ianniello, Ester Del Vescovo, Giulia Franceschini, Luciana Romaniello, Alberto Verrotti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

BACKGROUND: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with nocturnal polyuria and normal bladder function is desmopressin (dDAVP). OBJECTIVE: To evaluate if increasing dose of oral desmopressin lyophilisate (MELT) can improve response rates to dDAVP and is useful in enuretic children. MATERIALS AND METHODS: We enrolled a total of 260 children all diagnosed with NE. Enuretic children were treated with increasing MELT at a dose of 120, 180 and 240 mcg a day. RESULTS: We included in our study a total of 237 children, 164 males (69.2%) and 73 females (30.8%) aged between 5 and 18 years (mean age 10.32 ± 2.52 years). Of the 237 patients enrolled in the study and treated with MELT 120 mcg, a full response was achieved in 135 (56.9%). A partial response was achieved in 21 (8.9%) patients, therefore the dose was increased up to 180 mcg, with further improving symptoms (14.3%) or full response (9.5%), and up to 240 mcg, without usefulness. CONCLUSIONS: MELT at the dose of 120 mcg resulted efficacy and safety; the increased dose up to 180 mcg resulted poorly efficacy; finally, the further increase up to 240 mcg did not improve the symptoms with the increased risk of side effects.
Lingua originaleEnglish
pagine (da-a)127-129
Numero di pagine3
RivistaArchivio Italiano di Urologia Andrologia
Volume90
DOI
Stato di pubblicazionePubblicato - 2018

Keywords

  • Desmopressin
  • Nocturnal enuresis

Fingerprint

Entra nei temi di ricerca di 'Desmopressin 120 mcg, 180 mcg, 240 mcg: The right treatment for the right patient'. Insieme formano una fingerprint unica.

Cita questo